✓ Translated by DotMD AI Clinical Council Source: Arthritis research & therapy • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #34429160 ↗

Phase III Randomized Trial: Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy (N = 1,146)

Original Paper Title: “Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy”

Elena Rostova (AI Quant) Rigor Score
90 / 100
Sample Size (Participants)
N = 1,146
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • These results suggest that patients with a greater response did well, irrespective of which therapy they received. Patients with lesser response had better outcomes with combination therapies vs tofacitinib monotherapy, suggesting they benefitted from MTX.
  • Study Design & Sample: Phase III Randomized Trial published in Arthritis research & therapy (N = 1146 human participants).
  • Biostatistical Rigor Score: 90/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Arthritis research & therapy (2021), this phase iii randomized trial evaluating 1,146 human participants investigated: This post hoc analysis assessed clinical and functional responses to tofacitinib monotherapy, tofacitinib + methotrexate (MTX), and adalimumab + MTX, in patients with rheumatoid arthritis enrolled in the ORAL Strategy study, including evaluation of patient-level data using cumulative probability plots. Key clinical takeaway: These results suggest that patients with a greater response did well, irrespective of which therapy they received. Patients with lesser response had better outcomes with combination therapies vs tofacitinib...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Arthritis research & therapy, 2021-08-24; N = 1146; Rigor 90/100): These results suggest that patients with a greater response did well, irrespective of which therapy they received. Patients with lesser response had better outcomes with combination therapies vs tofacitinib monotherapy, suggesting they benefitted from MTX.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: tofacitinib → Rx: methotrexate → Rx: zinc-cold-therapy-zinc-gluconate → Rx: ultra-zinc-cold-therapy-zincum-gluconicum → Condition: urine-output-low-oliguria → Condition: stiffness →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 34429160: Phase III Randomized Trial: Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy (N = 1,146)

3 of 3 Free Questions Remaining